tbi-1301
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02366546)
Timeline
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, active
Cancer/testis antigen 1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tbi-1301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07174427 | Phase 3 | Nov 30, 2025 | Takara Bio Inc. |
| NCT03250325 | Phase 1/Phase 2 (Phase 2) | Sep 20, 2017 | Takara Bio Inc. |
| NCT02869217 | Phase 1 | Sep 1, 2016 | Takara Bio Inc., University of Toronto |
| NCT02366546 | Phase 1 | Mar 1, 2015 | Fiverings Co., Ltd., Mie University, Shionogi, Statcom Co. Ltd., Takara Bio Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takara Bio Inc. | For profit | 4 | 2 | 3 | 2015 |
| Fiverings Co., Ltd. | For profit | 1 | 0 | 1 | 2015 |
| Mie University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Shionogi | For profit | 1 | 0 | 1 | 2015 |
| Statcom Co. Ltd. | For profit | 1 | 0 | 1 | 2015 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2016 |
6 organizations
Page 1 / 1